{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:01:39Z","timestamp":1790614899731,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013130","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000}}],"reference-count":141,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013130.pub2","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T07:06:15Z","timestamp":1646982375000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome"],"prefix":"10.1002","volume":"2022","author":[{"given":"Audrey","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology; University of Minnesota Medical School; Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayanne","family":"Olabi","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Lothian University Hospitals NHS Trust, Lauriston Building; Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Langley","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine; The Ottawa Hospital and the University of Ottawa; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beecker","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine; The Ottawa Hospital and the University of Ottawa; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mutter","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine; The Ottawa Hospital; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Shelley","sequence":"additional","affiliation":[{"name":"Division of Dermatology; University of Toronto; Toronto\u00a0 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Worley","sequence":"additional","affiliation":[{"name":"Florida Dermatology and Skin Cancer Centers; Lake Wales Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program; Ottawa Hospital Research Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Saavedra","sequence":"additional","affiliation":[{"name":"Department of Dermatology; University of Virginia Health System; Charlottesville USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roses","family":"Parker","sequence":"additional","affiliation":[{"name":"Musculoskeletal, Oral, Skin and Sensory Network; Oxford University Hospitals NHS Foundation Trust Second Floor, OUH Cowley Unipart House Business Centre; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Stewart","sequence":"additional","affiliation":[{"name":"Cochrane Children and Families Network, c\/o Cochrane Pregnancy and Childbirth, Department of Women's and Children's Health; The University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Pardo Pardo","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0001|cit1","first-page":"158","article-title":"Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"20","author":"Azfar","year":"2010","journal-title":"Journal of Pakistan Association of Dermatologists"},{"issue":"10","key":"10.1002\/14651858.CD013130.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","article-title":"Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches","volume":"137","author":"Gonz\u00e1lez-Herrada","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Han F Zhang J Guo Q Feng Y Gao Y Guo L Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study Journal of Critical Care 2017 42 65 8","DOI":"10.1016\/j.jcrc.2017.07.002"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4103\/0378-6323.113080","article-title":"Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases","volume":"79","author":"Jagadeesan","year":"2013","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s004310050561","article-title":"Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children","volume":"156","author":"Kakourou","year":"1997","journal-title":"European Journal of Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD013130.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.burns.2014.01.027","article-title":"Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study","volume":"40","author":"Paquet","year":"2014","journal-title":"Burns"},{"issue":"Suppl 97","key":"10.1002\/14651858.CD013130.pub2-BIB0007|cit7","first-page":"140","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course","volume":"68","author":"Agrawal","year":"2013","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013130.pub2-BIB0008|cit8","first-page":"46","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course","volume":"175","author":"Saraogi","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"Journal of Clinical Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013130.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S0923-1811(98)83259-3","article-title":"Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group","volume":"16","author":"Wolkenstein","year":"1998","journal-title":"Journal of Dermatological Science"},{"issue":"9140","key":"10.1002\/14651858.CD013130.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4212\/cjhp.v71i4.2829","article-title":"Successful treatment of Stevens-Johnson Syndrome with cyclosporine and corticosteroid","volume":"71","author":"Auyeung","year":"2018","journal-title":"Canadian Journal of Hospital Pharmacy"},{"issue":"6","key":"10.1002\/14651858.CD013130.pub2-BIB0013|cit13","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0377-1237(08)80115-3","article-title":"Toxic epidermal necrolysis\u00a0managed with immunoglobulin","volume":"64","author":"Agarwal","year":"2008","journal-title":"Medical Journal, Armed Forces India"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2133.2006.07635.x","article-title":"Ciclosporin use in toxic epidermal necrolysis","volume":"156","author":"Danby","year":"2007","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0016|cit16","first-page":"370","article-title":"Toxic epidermal necrolysis treated with intravenous immunoglobulin","volume":"56","author":"De Juan Martin","year":"2002","journal-title":"Anales\u00a0Espanoles de Pediatria"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0017|cit17","first-page":"127","article-title":"Toxic epidermal necrolysis: treatment with cyclophosphamide","volume":"7","author":"Del Pozo","year":"1996","journal-title":"Journal of Dermatological Treatment"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1684\/ejd.2019.3518","article-title":"Intravenous immunoglobulins for delayed wound healing associated with toxic epidermal necrolysis","volume":"29","author":"Dequidt","year":"2019","journal-title":"European Journal of Dermatology: EJD"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0019|cit19","first-page":"270","article-title":"Systemic corticosteroids in toxic epidermal necrolysis","volume":"62","author":"Dhar","year":"1996","journal-title":"Indian Journal of Dermatology, Venereology, and Leprology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0020|cit20","first-page":"S72","article-title":"Etanercept for toxic epidermal necrolysis: a confirm on efficacy and safety","volume":"1","author":"Didona","year":"2015","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0021|cit21","first-page":"29","article-title":"Use of etanercept in a series of pediatric\u00a0patients\u00a0with Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis\u00a0spectrum disease","volume":"29","author":"Eliades","year":"2020","journal-title":"JAMA Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD013130.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/archdermatol.2011.1610","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis","volume":"147","author":"Feldmeyer","year":"2011","journal-title":"Archives of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD013130.pub2-BIB0023|cit23","first-page":"1048","article-title":"Erratum","volume":"69","year":"2013","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaad.2014.06.027","article-title":"Expression of Concern","volume":"71","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaad.2011.12.014","article-title":"Toxic epidermal necrolysis: five years of treatment experience from a burn unit","volume":"67","author":"Firoz","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1111\/ijd.14666","article-title":"Lower than expected mortality with dexamethasone in toxic epidermal necrolysis: 30-year experience of a Northern Mexico reference hospital","volume":"59","author":"Gomez-Flores","year":"2020","journal-title":"International Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Annals of Surgery"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0190-9622(08)81770-7","article-title":"Efficacy of cyclophosphamide in toxic epidermal necrolysis","volume":"28","author":"Hertl","year":"1993","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2013.04.007","article-title":"Methylprednisolone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers","volume":"69","author":"Hirahara","year":"2013","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD013130.pub2-BIB0030|cit30","first-page":"1494","article-title":"Treatment of polymorph erythema and Stevens-Johnson syndrome","volume":"109","author":"Journet","year":"1980","journal-title":"Union Medicale du Canada"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/ijd.14300","article-title":"Cyclosporine-induced toxic leukoencephalopathy in toxic epidermal necrolysis","volume":"58","author":"Kaushik","year":"2019","journal-title":"International Journal of Dermatology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0032|cit32","first-page":"61","article-title":"Plasmapheresis in the combined therapy of Lyell's syndrome","volume":"2","author":"Khapii","year":"1987","journal-title":"Anesteziologiia\u00a0I Reanimatologiia"},{"issue":"7","key":"10.1002\/14651858.CD013130.pub2-BIB0033|cit33","first-page":"766","article-title":"The effect of high-dose intravenous immunoglobulin for the treatment of toxic epidermal necrolysis","volume":"40","author":"Kim","year":"2002","journal-title":"Korean Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jbcr\/irz073","article-title":"Toxic Epidermal Necrolysis\u00a0therapy with TPE and IVIG-10 years of experience of the Burns Treatment Center","volume":"40","author":"Krajewski","year":"2019","journal-title":"Journal of Burn Care & Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013130.pub2-BIB0035|cit35","first-page":"P01","article-title":"Cytokine profile in 133 patients with severe cutaneous adverse reactions","volume":"8","author":"Lalevee","year":"2018","journal-title":"Clinical and Translational Allergy"},{"issue":"8","key":"10.1002\/14651858.CD013130.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ijd.12702","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience","volume":"54","author":"Lalosevic","year":"2015","journal-title":"International Journal of Dermatology"},{"issue":"7-8","key":"10.1002\/14651858.CD013130.pub2-BIB0037|cit37","first-page":"467","article-title":"Immunomodulating therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"75","author":"Mockenhaupt","year":"2000","journal-title":"H+G Zeitschrift fur Hautkrankheiten"},{"issue":"7","key":"10.1002\/14651858.CD013130.pub2-BIB0038|cit38","first-page":"601","article-title":"FR-ciclosporin as a first-line treatment in epidermal necrolysis","volume":"110","author":"Morgado-Carrasco","year":"2019","journal-title":"Actas Dermo-Sifiliograficas"},{"issue":"Suppl 106","key":"10.1002\/14651858.CD013130.pub2-BIB0039|cit39","first-page":"30","article-title":"Aetiopathogenesis of severe cutaneous adverse reactions (SCARS) in children: a 9-year experience in a tertiary-care paediatric hospital setting","volume":"74","author":"Mori","year":"2019","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0040|cit40","unstructured":"Study to evaluate the use of palifermin to treat toxic epidermal necrolysis clinicaltrials.gov\/ct2\/show\/NCT02037347"},{"issue":"6493","key":"10.1002\/14651858.CD013130.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.291.6493.485-a","article-title":"Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis","volume":"291","author":"Nixon","year":"1985","journal-title":"British Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD013130.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.jid.2018.03.1496","article-title":"Selective use of cyclosporine for Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis\u00a0may exclude patients with poor prognostic factors","volume":"138","author":"Noe","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.0906-6705.2006.00426.x","article-title":"Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis","volume":"15","author":"Paquet","year":"2006","journal-title":"Experimental Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2500\/108854192778878926","article-title":"Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS","volume":"13","author":"Patterson","year":"1992","journal-title":"Allergy and Asthma Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.burns.2019.11.011","article-title":"Re: Combination therapy for Toxic Epidermal Necrolysis: It is time for anti-TNFa biologics comparison","volume":"46","author":"Pham","year":"2020","journal-title":"Burns"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0046|cit46","first-page":"581","article-title":"Beneficial effect of hyperbaric oxygen on toxic epidermal necrolysis and pemphigus vulgaris","volume":"35","author":"Pisani","year":"1981","journal-title":"Annali\u00a0Italiani di Dermatologia Clinica e\u00a0Sperirentale"},{"issue":"47","key":"10.1002\/14651858.CD013130.pub2-BIB0047|cit47","first-page":"4273","article-title":"The treatment of acute epidermal necrolysis (Lyell's syndrome). The contribution of two recent techniques","volume":"7","author":"Revuz","year":"1978","journal-title":"La Nouvelle Presse\u00a0Medicale"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/0019-5154.147834","article-title":"Severe cutaneous adverse drug reactions: a clinicoepidemiological study","volume":"60","author":"Sasidharanpillai","year":"2015","journal-title":"Indian Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2018.09.063","article-title":"Use of cyclosporine for the treatment of Steven Johnson Syndrome\/Toxic Epidermal Necrolysis","volume":"85","author":"Shah","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013130.pub2-BIB0051|cit51","first-page":"16","article-title":"Patterned behaviour and response to current treatments among children with Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum: a prospective study","volume":"59","author":"Sudusinghe","year":"2018","journal-title":"Australian Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD013130.pub2-BIB0052|cit52","first-page":"1674","article-title":"Clinical efficacy of hemoperfusion in 10 children with severe drug eruption","volume":"28","author":"Tao","year":"2013","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013130.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1046\/j.1365-2133.1998.2576n.x","article-title":"Severe bullous drug reactions treated successfully with cyclophosphamide","volume":"139","author":"Trautmann","year":"1998","journal-title":"British Journal of Dermatology"},{"issue":"5388","key":"10.1002\/14651858.CD013130.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0055|cit55","first-page":"WK0718","article-title":"Thalidomide and emergent conditions","volume":"129","author":"Wolkenstein","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2230.2005.01863.x","article-title":"The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"30","author":"Yeung","year":"2005","journal-title":"Clinical and Experimental Dermatology: Viewpoints in Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1468-3083.2011.04143.x","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008","volume":"26","author":"Zajicek","year":"2012","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/15569527.2016.1141416","article-title":"Toxic epidermal necrolysis: 13 years of experience in the management at a Department of Dermatology in China","volume":"36","author":"Zhang","year":"2017","journal-title":"Cutaneous and Ocular Toxicology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0059|cit59","unstructured":"Use of glucocorticoid alone or plus intravenous immunoglobulin(IVIG) for the treatment of severe drug eruption apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-TRC-13003550"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0060|cit60","unstructured":"G-CSF in the treatment of toxic epidermal necrolysis clinicaltrials.gov\/ct2\/show\/NCT02739295"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0061|cit61","unstructured":"NATIENS: Optimal management and mechanisms of SJS\/TEN (NATIENS) clinicaltrials.gov\/show\/NCT02987257"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0062|cit62","unstructured":"Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis clinicaltrials.gov\/show\/NCT03585946"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Ar\u00e9valo","year":"2000","journal-title":"Journal of Trauma"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ijd.12423","article-title":"Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies","volume":"54","author":"Barron","year":"2015","journal-title":"International\u00a0Journal of\u00a0Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD013130.pub2-BIB0067|cit67","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Dermato-Venereologica"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD013130.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"},{"issue":"6982","key":"10.1002\/14651858.CD013130.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0071|cit71","unstructured":"Covidence Veritas Health Innovation 2018"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0072|cit72","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 10. Analyzing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2133.2009.09585.x","article-title":"Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected]","volume":"162","author":"Sica-Chapman","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0625.1995.tb00211.x","article-title":"Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"4","author":"Dietrich","year":"1995","journal-title":"Experimental Dermatology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0075|cit75","unstructured":"Dijkers M Introducing GRADE: a systematic approach to rating evidence in systematic reviews and to guideline development ktdrr.org\/products\/update\/v1n5\/dijkers_grade_ktupdatev1n5.pdf"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaad.2015.08.008","article-title":"Treatment of toxic epidermal necrolysis in North America","volume":"73","author":"Dodiuk-Gad","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0077|cit77","volume-title":"Finding What Works in Health Care: Standards for Systematic Reviews","author":"Institute of Medicine (US) Committee on Standards for Systematic Reviews of Comparative Effectiveness Research","year":"2011"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0078|cit78","unstructured":"Campbell MK Campbell MJ Drahota AK Reeves BC Revised Cochrane risk of bias tool for randomized trials (RoB 2). Additional considerations for cluster-randomized trials (RoB 2 CRT) www.riskofbias.info\/welcome\/rob-2-0-tool\/rob-2-for-cluster-randomized-trials"},{"issue":"6","key":"10.1002\/14651858.CD013130.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1345\/aph.1K001","article-title":"Etanercept for toxic epidermal necrolysis","volume":"41","author":"Famularo","year":"2007","journal-title":"Annals of Pharmacotherapy"},{"issue":"15","key":"10.1002\/14651858.CD013130.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2165\/00003495-200565150-00002","article-title":"Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date","volume":"65","author":"Faye","year":"2005","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0081|cit81","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1346-8138.2009.00616.x","article-title":"Toxic epidermal necrolysis successfully treated with etanercept","volume":"36","author":"Gubinelli","year":"2009","journal-title":"Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","article-title":"Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Reviews"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2050313X2093470","DOI":"10.1177\/2050313X20934708","article-title":"Intravenous N-acetylcysteine in severe cutaneous drug reaction treatment: a case series","volume":"8","author":"Hasan","year":"2020","journal-title":"SAGE Open Medical Case Reports"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0085|cit85","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0086|cit86","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from\u00a0www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0087|cit87","unstructured":"Higgins JPT Li T Chapter 23: Including variants on randomized trials.\u00a0In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0088|cit88","unstructured":"Hoffman M Chansky PB Bashyam AR Boettler MA Challa N Dominguez A Long-term physical and psychological outcomes of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis JAMA Dermatology 10.1001\/jamadermatol.2021.1136 33950191"},{"issue":"7","key":"10.1002\/14651858.CD013130.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"Journal of Investigative Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD013130.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2230.1997.tb01044.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor","volume":"22","author":"Jarrett","year":"1997","journal-title":"Clinical and Experimental Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/clin.1996.0181","article-title":"Thalidomide as an anti-TNF-\u03b1 inhibitor: implications for clinical use","volume":"81","author":"Klausner","year":"1996","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2015.10.002","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis \u2013 a comprehensive review and guide to therapy. I. Systemic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocular Surface"},{"issue":"8","key":"10.1002\/14651858.CD013130.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ijd.12702","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience","volume":"54","author":"Lalosevic","year":"2015","journal-title":"International Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1060028014560012","article-title":"Corticosteroids in Stevens-Johnson Syndrome\/toxic epidermal necrolysis: current evidence and implications for future research","volume":"49","author":"Law","year":"2015","journal-title":"Annals of\u00a0Pharmacotherapy"},{"issue":"399","key":"10.1002\/14651858.CD013130.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2307\/2288790","article-title":"Regression methods for Poisson process data","volume":"82","author":"Lawless","year":"1986","journal-title":"Journal of the American Statistical Association"},{"issue":"7","key":"10.1002\/14651858.CD013130.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.burns.2014.02.006","article-title":"A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres","volume":"40","author":"Mahar","year":"2014","journal-title":"Burns"},{"issue":"12","key":"10.1002\/14651858.CD013130.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2020","journal-title":"Research Synthesis Methods"},{"issue":"6","key":"10.1002\/14651858.CD013130.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"E303","DOI":"10.1016\/j.jaad.2013.07.036","article-title":"Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases","volume":"69","author":"Napolitano","year":"2013","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD013130.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/nm1208-1311","article-title":"Saving the skin from drug-induced detachment","volume":"14","author":"Nickoloff","year":"2008","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0103|cit103","unstructured":"Page MJ Higgins JPT Sterne JAC Chapter 13. Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3\u00a0(updated February\u00a02022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.110749","article-title":"A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population","volume":"79","author":"Patel","year":"2013","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"915314","DOI":"10.1155\/2012\/915314","article-title":"Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient","volume":"2012","author":"Patmanidis","year":"2012","journal-title":"Case Reports in Dermatological Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013130.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Ciclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients - exposed\/unexposed and propensity-score matched analyses","volume":"138","author":"Poizeau","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Archives of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013130.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4103\/0378-6323.41379","article-title":"Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis","volume":"74","author":"Rai","year":"2008","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0110|cit110","first-page":"24","article-title":"Cyclosporine for SJS\/TEN: a case series and review of the literature","volume":"87","author":"Reese","year":"2011","journal-title":"Cutis"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0111|cit111","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0112|cit112","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2020"},{"issue":"9","key":"10.1002\/14651858.CD013130.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Archives of Dermatology"},{"issue":"1-2","key":"10.1002\/14651858.CD013130.pub2-BIB0114|cit114","first-page":"31","article-title":"Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF","volume":"32","author":"Robak","year":"2001","journal-title":"Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0115|cit115","first-page":"229","article-title":"Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin","volume":"143","author":"Romanelli","year":"2008","journal-title":"Giornale Italiano di Dermatologia e Venereologia"},{"issue":"24","key":"10.1002\/14651858.CD013130.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2020.12.080","article-title":"Biologic treatment in pediatric Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review","volume":"85","author":"Sachdeva","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0118|cit118","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Guyatt GH Chapter 14. Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. \u00a0In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0119|cit119","unstructured":"Schunemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 15. Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/pde.12029","article-title":"Toxic epidermal necrolysis in a child successfully treated with infliximab","volume":"31","author":"Scott-Lang","year":"2014","journal-title":"Pediatric Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4103\/0378-6323.116738","article-title":"Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid","volume":"79","author":"Singh","year":"2013","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-1: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013130.pub2-BIB0125|cit125","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD013130.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Mockenhaupt","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1440-0960.1996.tb01057.x","article-title":"Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management","volume":"37","author":"Sullivan","year":"1996","journal-title":"Australian Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience","volume":"139","author":"Trent","year":"2008","journal-title":"Archives of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"5388","key":"10.1002\/14651858.CD013130.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: Building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology Practice"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-0462","article-title":"Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis","volume":"88","author":"Wojtkiewicz","year":"2008","journal-title":"Acta Dermato-Venereologica"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergy International"},{"issue":"11","key":"10.1002\/14651858.CD013130.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"e0165933","DOI":"10.1371\/journal.pone.0165933","article-title":"Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a nationwide population-based study using national health insurance database in Korea","volume":"11","author":"Yang","year":"2016","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1002\/14651858.CD013130.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.1995.tb02649.x","article-title":"Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin","volume":"133","author":"Zaki","year":"1995","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD013130.pub2-BIB0138|cit138","first-page":"61","article-title":"Toxic epidermal necrolysis successfully treated with infliximab","volume":"23","author":"Z\u00e1rate-Correa","year":"2013","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD013130.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating\u00a0therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD013130.pub2-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013130","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","author":"Langley","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013130.pub2-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001435","article-title":"Interventions for toxic epidermal necrolysis","author":"Majumdar","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T12:12:11Z","timestamp":1704197531000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013130.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":141,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013130.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]}}}